profit from every $100 of sales.
$0$100
YD Bio Limited Ordinary Shares
$4.88-6.06% today
-51.8% in 1 year
1-year low $1.901-year high $15.42
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What YD Bio Limited Ordinary Shares sold, what it kept, and what it did with the cash.
Sales went from $350,131 in 2023 to $596,817 in 2025, with -$8.31 million of profit last year.
SalesProfit
YD Bio Limited Ordinary Shares vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| YD Bio Limited Ordinary Shares | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads YD Bio Limited Ordinary Shares's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| 0 | 1 | 1 | |
| 0 | 0 | 0 | |
| -0 | -1 | -5 | |
| 0 | -1 | -8 | |
| 0 | -1 | -8 | |
| 0.00 | -0.02 | – | |
| 43.8% | 30.4% | 28.1% | |
| -2.0% | -286.5% | -882.7% | |
| 3.9% | -276.6% | -1,392.6% |
Balance sheet
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total assets | 0 | 7 | 14 |
| Cash | 0 | 3 | 6 |
| Total debt | 0 | 0 | 0 |
| Total liabilities | 0 | 0 | 17 |
| 0 | 7 | -3 | |
| 70 | 70 | – | |
| 22.2% | -16.6% | – | |
| 59.0% | -21.4% | 291.0% |
Cash flow
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| -0 | -1 | -7 | |
| 0 | 3 | 1 | |
| -0 | -4 | -8 | |
| Dividends paid | – | – | – |
| – | – | – | |
| – | – | – |
Valuation
- –
- –
- –
- -6.3×
- 579.2×
- –
- –
- -2.3%
- -2.4%
- 0.0%
Profitability
- 28.1%
- -882.7%
- -1,392.6%
- 0.0%
- -9.3%
- 66.3%
- 80.8%
- -37.5%
- -9.3%
- –
Growth
- +30.6%
- –
- −69.3%
- –
- +46.1%
Financial health
- -0.7×
- -0.00
- 0.0%
- –
- 5.88
- 4.74
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 28%of 946
Top 19%of 868
Bottom 30%of 986
News
E-L Financial Corporation Limited PFD 1ST SER 3 declares CAD 0.3438 dividendSeeking Alpha · Nov 11, 2026E-L Financial Corporation Limited PFD 1ST SER 1 declares CAD 0.3312 dividendSeeking Alpha · Nov 11, 2026E-L Financial Corporation Limited PFD 4.75% SR 2 declares CAD 0.2968 dividendSeeking Alpha · Nov 11, 2026New England Realty Associates Limited Partnership declares $0.40 dividendSeeking Alpha · Nov 9, 2026Johnson & Johnson (JNJ): Limited Analyst Upside, but Management Sees a Clearer Path to GrowthYahoo Finance · Nov 8, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/6Passes 1 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
48No pass
Benjamin Graham
45No pass
Philip Fisher
58No pass
Peter Lynch
–Not enough data
Joel Greenblatt
2No pass
Charlie Munger
57No pass
Terry Smith
60Pass
Questions about YD Bio Limited Ordinary Shares
Is YD Bio Limited Ordinary Shares a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the YD Bio Limited Ordinary Shares AI analysis
What does YD Bio Limited Ordinary Shares do?
Breeze Holdings Acquisition Corp. operates as a clinical-stage biopharmaceutical company focuses on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of a diseases with unmet medical need. It is in Biotechnology.
Does YD Bio Limited Ordinary Shares pay a dividend?
No. YD Bio Limited Ordinary Shares does not pay a dividend at the moment.
Is YD Bio Limited Ordinary Shares stock halal?
Yes. YD Bio Limited Ordinary Shares passes our halal screen: its business is permitted and its debt is under 0.1% of its market value, under the 30% limit. How we check
How has YD Bio Limited Ordinary Shares stock done over the past year?
Down 51.8% over the past twelve months, to $4.88. It traded between $1.90 and $15.42 and is 68.4% below its high.
Who are YD Bio Limited Ordinary Shares's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with YD Bio Limited Ordinary Shares's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.